Skip to main content

Table 1 Clinical features of 334 patients with B-iNHLs

From: Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Characteristics

Chemotherapy

Chemoimmunotherapy

Number of patients

206

128

Median Age, y (Range)

59 (26–87)

54 (19–82)

≤60, %

108 (52.4)

89 (69.5)

60-70

72 (35.0)

28 (21.9)

≥70

26 (12.6)

11 (8.6)

Male/Female, %

71/29

65.4/34.6

ECOG performance status, %

  

0

49.4

52.3

1-2

45.9

44.7

3

4.7

3.0

Leukocyte count, 109/L (range)

18.0 (83–382)

11.5 (63–300)1*

Hemoglobin, g/L (range)

113 (21–169)

112 (41–177)

Thrombocyte count, 109/L (range)

120 (4–759)

136 (10–577)

β2-microglobulin, mg/L (range)

3.69 (1–14.5)

3.41 (1–13.4)

LDH, U/L (range)

166 (16–977)

164 (17–1892)

CD20+ cells by flow cytometry, %

143/178 (80.3 %)

99/105 (94.3 %)2*

Cytogenetic abnormalities, %

  

Del (13q)

15/99 (15.2 %)

11/100 (11.0 %)

Del (17p)

13/91 (14.3 %)

13/87 (14.9 %)

IgH

27/99 (27.3 %)

39/102 (38.2 %)

ZAP70 positive

19/61 (31.1 %)

18/33 (54.5 %)3*

CD38 positive

38/146 (26.0 %)

36/85 (42.4 %)4*

Histology ( N)

  

CLL (151)

107

44

FL (41)

13

28

NMZL (11)

5

6

SMZL (13)

7

6

HCL (17)

14

3

LPL (36)

22

14

BLPD-U (65)

38

27

  1. CLL Chronic lymphocytic leukemia, FL Follicular lymphoma, NMZL Nodal marginal zone lymphoma, SMZL Splenic B-cell marginal zone lymphoma, LPL Lymphoplasmacytoid lymphoma, BLPD-U B lymphoproliferative disease–unclassified
  2. 1*P = 0.021; 2* P = 0.001; 3*P = 0.027; 4*P = 0.010
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us